Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly's tirzepatide has been shown to significantly ... is expected to unlock reimbursement coverage for GLP-1 drugs, ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Tirzepatide is one of a group of weight-loss drugs known as GLP-1 receptor agonists ... potential risks when used for the ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...